BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated ...
BridgeBio (BBIO) announced late-breaking preclinical data on BBO-10203, a covalent small molecule RAS:PI3Ka breaker that selectively and specifically blocks the physical interaction between RAS and ...
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results